[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:receptor-type-tyrosine-protein-kinase-flt3":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Receptor-Type Tyrosine-Protein Kinase FLT3",33,28,[8,16,23,30,36,43,49,55,61,67,73,79,85,91,97,103,109,115,121,127,133,139,145,151,157,163,169,175,181,188,195,202,208],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04293562","A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and\u002For Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations",[12],"Phase 3","RECRUITING","2026-08-26T02:15:30.699880Z","2026-05-05T02:43:29.285570Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06504459","Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML",[20],"Phase 2","2026-08-26T02:17:46.653867Z","2026-05-05T02:43:28.882922Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06313437","Revumenib in Combination With 7+3 + Midostaurin in AML",[27],"Phase 1","2026-08-26T02:16:56.877406Z","2026-05-05T02:43:28.835411Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06786533","Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed\u002FRefractory AML",[27],"2026-08-26T02:19:21.761002Z","2026-05-05T02:43:28.314976Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT03661307","Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome",[40],"Phase 1\u002FPhase 2","2026-08-26T02:18:00.873391Z","2026-05-05T02:43:28.288010Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT06158828","Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML",[40],"2026-08-26T02:18:22.309547Z","2026-05-05T02:43:28.284461Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT06285890","Phase I Study of HC-7366 for Acute Myeloid Leukemia",[27],"2026-08-26T02:15:34.659160Z","2026-05-05T02:43:28.182174Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT06152809","CIML NK Cells With Venetoclax for AML",[27],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:28.162326Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06222580","SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation",[27],"2026-08-26T02:16:27.227548Z","2026-05-05T02:43:27.620905Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06366789","Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia",[27],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:27.326010Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05756777","A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)",[27],"2026-08-26T02:18:23.582895Z","2026-05-05T02:43:27.248629Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT07011004","A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia",[27],"2026-08-26T02:15:26.669629Z","2026-05-05T02:43:27.130925Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT05735184","A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax\u002FAzacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML",[27],"2026-08-26T02:16:35.654046Z","2026-05-05T02:43:26.898008Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT06484062","Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes",[27],"2026-08-26T02:16:46.951087Z","2026-05-05T02:43:26.737999Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT05010122","ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",[40],"2026-08-26T02:16:39.977107Z","2026-05-05T02:43:26.718594Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06001788","Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia",[27],"2026-08-26T02:18:46.948970Z","2026-05-05T02:35:31.908076Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06824168","Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission",[20],"2026-08-26T02:17:48.768272Z","2026-05-05T02:35:31.869847Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT05886049","A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated\u002FFLT3 Wildtype or MLL\u002FKMT2A Rearranged or NUP98 Alterations Disease",[27],"2026-08-26T02:19:05.360997Z","2026-07-05T05:32:16.737825Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT07032727","Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations",[20],"2026-08-26T02:15:38.131683Z","2026-05-05T02:43:28.209956Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT03013998","Study of Biomarker-Based Treatment of Acute Myeloid Leukemia",[40],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:28.183972Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT07270978","Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS",[27],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:27.951482Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT06575296","Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant",[27],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:27.843378Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT04187105","BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)",[20],"2026-08-26T02:17:44.240289Z","2026-05-05T02:43:27.748653Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT04140487","Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent\u002FRefractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome\u002FMyeloproliferative Neoplasm",[40],"2026-08-26T02:18:31.164304Z","2026-04-29T02:57:57.109829Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT02727803","Personalized NK Cell Therapy in CBT",[20],"2026-08-26T02:18:36.226508Z","2026-05-05T02:43:29.030294Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT04099966","AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha\u002FBeta T Cell and CD19+ B Cell Depletion",[20],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:28.713058Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT07645469","FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia",[27],"2026-08-26T02:17:38.215063Z","2026-06-14T18:39:22.265217Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT03016806","Umbilical Cord Blood Transplantation From Unrelated Donors",[],"2026-08-26T02:15:21.365312Z","2026-05-13T02:55:06.119599Z",{"nct_id":182,"title":183,"phases":184,"status":185,"updated_at":186,"content_modified":187},"NCT02646839","KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL\u002FAML\u002FMDS Allo-HCT Children",[20],"ENROLLING_BY_INVITATION","2026-08-26T02:17:30.961790Z","2026-06-16T05:54:07.966507Z",{"nct_id":189,"title":190,"phases":191,"status":192,"updated_at":193,"content_modified":194},"NCT06235801","A Phase I\u002FII Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia",[40],"ACTIVE_NOT_RECRUITING","2026-08-03T03:27:21.703656Z","2026-05-05T02:43:28.304177Z",{"nct_id":196,"title":197,"phases":198,"status":199,"updated_at":200,"content_modified":201},"NCT05546580","Study of Iadademstat and Gilteritinib in Patients With R\u002FR AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)",[27],"UNKNOWN","2026-08-03T03:34:46.909700Z","2026-05-05T02:43:27.313681Z",{"nct_id":203,"title":204,"phases":205,"status":192,"updated_at":206,"content_modified":207},"NCT06445907","Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia",[27],"2026-08-03T01:57:10.726985Z","2026-05-05T02:43:27.037954Z",{"nct_id":209,"title":210,"phases":211,"status":192,"updated_at":212,"content_modified":213},"NCT04493138","Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic\u002FMyeloproliferative Neoplasm With FLT3 or CBL Mutations",[40],"2026-08-03T02:33:22.894436Z","2026-05-05T02:43:28.119922Z"]